Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

NCT02118584 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1822

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.

Conditions

Ulcerative Colitis

Interventions

DRUG: Etrolizumab

Sponsor

Hoffmann-La Roche